Regeneron Pharmaceuticals (REGN) Receivables - Net (2009 - 2026)

Regeneron Pharmaceuticals' Receivables - Net history runs 18 years deep, the most recent figure standing at $6.6 billion for Q2 2026.

• In Q2 2026, Receivables - Net rose 17.03% year-over-year to $6.6 billion; the TTM figure through Jun 2026 stood at $6.6 billion (up 17.03% YoY), while the FY2025 annual figure was $5.7 billion, down 7.58% from the prior year.
• Receivables - Net for Q2 2026 stood at $6.6 billion, up from $5.7 billion in the prior quarter.
• The five-year high for Receivables - Net was $6.6 billion in Q2 2026, with the low at $4.8 billion in Q1 2022.
• The 5-year median for Receivables - Net is $5.6 billion (2023), against an average of $5.6 billion.
• The sharpest annual moves came in 2022 and 2026: Receivables - Net slipped 26.25% in 2022, then climbed 17.03% in 2026.
• Regeneron Pharmaceuticals' Receivables - Net stood at $5.3 billion in 2022, then gained by 6.35% to $5.7 billion in 2023, then grew by 9.61% to $6.2 billion in 2024, then retreated by 7.58% to $5.7 billion in 2025, then increased by 14.36% to $6.6 billion in 2026.
• Business Quant data shows REGN's Receivables - Net at $6.6 billion in Q2 2026, $5.7 billion in Q1 2026, and $5.7 billion in Q4 2025.